Association between clinical use of lansoprazole and the risk of type 2 diabetes mellitus: A pharmacoepidemiological cohort study

Background: Proton pump inhibitors (PPIs) are common and widely used for gastrointestinal-related disorders. Lansoprazole is one of PPIs with potential benefits of anti-inflammation, reduced oxidative stress, and anti-diabetes. The aims of this study are to determine whether lansoprazole imparts differential risk of type 2 diabetes as compared with other PPIs. Methods A population-based retrospective cohort study was conducted using the National Health Insurance Research Database in Taiwan. Patients who received lansoprazole more than 90 days and without records of use of other PPIs between January 1, 2000 and December 31, 2005 (the exposure period) were considered as the exposed cohort (n = 1,668). In comparison, patients who received other PPIs more than 90 days and without use of lansoprazole in the exposure period were treated as the unexposed cohort (n = 3,336).The primary outcome was the new-onset of type 2 diabetes mellitus (T2DM). The association between lansoprazole use and the risk of T2DM was determined by hazard ratios (HRs) and 95% confidence intervals (CIs) derived from multivariable Cox proportional hazards models. Results The lansoprazole cohort showed a significantly reduced risk of T2DM with an adjusted HR of 0.65 (95% CI, 0.56–0.76). Interestingly, the inverse association between use of lansoprazole and risk of T2DM was observed in both men and women and in various age groups. Conclusion Our findings suggest that lansoprazole was associated with a reduced risk of T2DM compared with other PPIs. Further studies are needed to determine the clinical implications of the present study.